Latest Breaking News On - கரோலின் ரூஃபோ - Page 1 : comparemela.com

(0) Forendo Pharma, a clinical-stage drug development company focusing on novel treatments in women s health, today announced the completion of Phase 1 studies in healthy volunteers for its lead development program in endometriosis, FOR-6219, and provided a development outlook. The successfully concluded Phase 1 program demonstrated that FOR-6219, a HSD17B1 enzyme-targeting small-molecule, was safe and well-tolerated and delivered additional results supporting Forendo s therapeutic concept. The company is now planning the Phase 2 program including endometriosis patients in the US. The now completed Phase 1 program delivered an initial body of tolerability, safety and pharmacokinetic data. For chronic endometriosis treatment, tolerability and a lack of systemic estrogen deficiency-related side effects are of the utmost importance as we see current therapies struggling to be widely adopted due to their side effect profiles. A local effect on the target tissue with our intracrinolog

Kostenloser wertpapierhandelForendo pharmaCaroline rufoRisto lammintaustaKarolinska developmentNovartis venture fundEnovo seedsVesalius biocapitalSunstone life scienceDougall advisorsகரோலின் ரூஃபோநோவர்த்திச் துணிகர நிதிநோவோ விதைகள்சன்ஸ்டோன் வாழ்க்கை அறிவியல்